• Foscarnet prophylaxis improved engraftment and survival in cord blood transplant patients

    Six-month overall survival was 96% in the treated group compared to 72% in the untreated group.

  • Latent HHV-6B infection of astrocytes may increase the risk of depression by activating the HPA axis

    Japanese investigators show that a protein expressed by latent HHV-6B in astrocytes, results in an influx of extra-cellular calcium, triggering the onset of depression.

  • Mothers with iciHHV6 have an increased risk of spontaneous abortion

    27.6% of Japanese mothers with iciHHV6 had a spontaneous abortion compared to 14.8% of controls. iciHHV6 mothers were also 6.4X more likely to have two or more spontaneous abortions.

  • Significantly worse outcomes in critically ill hematology patients associated with HHV-6 infection.

    Two reports associate detectable HHV-6 DNA in body fluids with increased risk of mortality in patients being treated for hematologic malignancies.

Newsletter | About Us | Contact Us | Donate | Repository

HHV-6 Foundation | HHV-6 Disease Information for Patients, Clinicians, and Researchers | Apply for a Grant Navigation
  • Home
  • About
    • Scientific Office
    • Scientific Advisory Board
    • Executive Director & Staff
    • Board of Directors
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
    • HHV-6 Treatment
    • Patient FAQ
    • Conditions Associated with HHV-6
    • HHV-6 & Immune Suppression
    • Immune Stimulants
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
  • Research
    • Latest HHV-6 Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter
  • Clinicians
    • HHV-6A/B Testing
    • HHV-6 Treatment
      • HHV-6 Antivirals
      • Immune Stimulants
    • Alternative Treatments
      • Antiviral use in transplant patients with HHV-6 encephalitis
      • More about foscarnet, ganciclovir and cidovofir
    • HHV-6 & Immune Suppression
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
    • 10 Surprising Facts about CIHHV-6
  • Conditions
    • Associated Conditions A-H
      • Amnesia
      • Cancer
      • Chromosomally Integrated HHV-6 (ciHHV-6)
      • Chronic Fatigue Syndrome
      • Cognitive Dysfunction
      • Colitis/Diarrhea
      • Drug Hypersensitivity
      • Encephalitis
      • Endocrine Disorders
      • Endothelial Cell Dysfunction
      • Epilepsy
      • Heart Disease
      • HIV/AIDS Progression
    • Associated Conditions I-Z
      • Immune Suppression
      • Kidney Disease
      • Liver Disease
      • Lung Disease
      • Mononucleosis/Lymphadenopathy
      • Multiple Sclerosis
      • Neurological Conditions
      • Organ-Specific Diseases
      • Rash/Roseola
      • Transplant Complications
  • Home
  • About
    • Scientific Office
    • Scientific Advisory Board
    • Executive Director & Staff
    • Board of Directors
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
    • HHV-6 Treatment
    • Patient FAQ
    • Conditions Associated with HHV-6
    • HHV-6 & Immune Suppression
    • Immune Stimulants
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
  • Research
    • Latest HHV-6 Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter
  • Clinicians
    • HHV-6A/B Testing
    • HHV-6 Treatment
      • HHV-6 Antivirals
      • Immune Stimulants
    • Alternative Treatments
      • Antiviral use in transplant patients with HHV-6 encephalitis
      • More about foscarnet, ganciclovir and cidovofir
    • HHV-6 & Immune Suppression
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
    • 10 Surprising Facts about CIHHV-6
  • Conditions
    • Associated Conditions A-H
      • Amnesia
      • Cancer
      • Chromosomally Integrated HHV-6 (ciHHV-6)
      • Chronic Fatigue Syndrome
      • Cognitive Dysfunction
      • Colitis/Diarrhea
      • Drug Hypersensitivity
      • Encephalitis
      • Endocrine Disorders
      • Endothelial Cell Dysfunction
      • Epilepsy
      • Heart Disease
      • HIV/AIDS Progression
    • Associated Conditions I-Z
      • Immune Suppression
      • Kidney Disease
      • Liver Disease
      • Lung Disease
      • Mononucleosis/Lymphadenopathy
      • Multiple Sclerosis
      • Neurological Conditions
      • Organ-Specific Diseases
      • Rash/Roseola
      • Transplant Complications
View Post

The role of OX40 in DIHS/DRESS and HHV-6 reactivation

OX40 levels distinguished DIHS/DRESS from other inflammatory dermatologic conditions, and were associated with HHV-6 reactivation

View Post

HHV-6 as a trigger for chronic fatigue syndrome: a meta-analysis

Systematic review and meta-analysis confirm an association, but not a causal link, between HHV-6 and CFS

View Post

Viral reactivation may be one cause of febrile neutropenia in chemotherapy patients

HHV-6 was the most prevalent virus in febrile neutropenia episodes among pediatric patients

View Post

A relationship between human endogenous retroviruses and HHV-6A/B in multiple sclerosis patients

Significant positive correlations were found between HERV family proteins and antibodies to HHV-6A/B but not antibodies to EBV

View Post

The U20 and U21 genes of HHV-6A downregulate NK cell attack

U20/21 genes may help HHV-6A evade immune response

View Post

CMV infection may diminish the risk of developing MS

Studies conducted on serum obtained before development of MS indicate possible protective role

View Post

HHV-6 miRNA inhibits host miRNA to trigger reactivation from latency

A viral miRNA disrupts mitochondrial architecture, suppresses type I interferon production, is necessary for productive infection and for virus reactivation, all by inhibiting multiple members of the host miR-30 family—creating a therapeutic target to suppress reactivation.

View Post

Seronegative pediatric liver transplant patients frequently acquire clinically significant HHV-6 infections from the donor liver or accompanying leucocytes

HHV-6 seronegativity pre-transplantation predicts HHV-6 viremia post-transplantation

View Post

4C-seq genomic methodology used to examine HHV-6A integration sites

Chromatin interactions help silence transcription of HHV-6A genes following integration

View Post

The effects of HHV-6B infection on immune checkpoint inhibition

HHV-6B infection of primary monocytes induces cell-associated and soluble PD-L1 production, increased intracellular ROS and activation of STAT1 and STAT3 pathways

View Post

Breakthrough reactivation of HHV-6 occurs with liver transplantation in spite of valganciclovir preemptive therapy for CMV

High-grade HHV-6 viremia is independently associated with rejection of liver transplants within 12 months

View Post

Adult patients with lower levels of anti-HHV-6 IgG are significantly more likely to experience HHV-6 reactivation following cord blood transplant

Patients with low levels of HHV-6 antibodies might benefit from treatment from IVIG or novel neutralizing antibodies before cord blood transplantation

View Post

The importance of individual glycoprotein components of the HHV-6A/6B envelope tetramer on essential viral functions

The combination of gQ1 and gQ2 tetramer components of both HHV-6A/6B are important for viral propagation, probably by affecting attachment to their different receptors.

View Post

Reactivation of herpesviruses demonstrated in severely ill patients with acute COVID-19

EBV, CMV, and HHV-6 reactivation were found in a small cohort of severe COVID-19 patients

View Post

Quantitative PCR of serum found superior to whole blood in differentiating between latent virus and viremia following cord blood transplantation

Use of serum more easily distinguishes viremia from latent virus

  • Page 1 of 20
  • 1
  • 2
  • 3
  • ...
  • 20
  • →

Clinical News

  • Alzheimer’s Disease
  • Animal Models
  • Autoimmune Disease
  • Cancer
  • Chronic Fatigue Syndrome
  • iciHHV-6
  • CNS Disease
  • Drug Hypersensitivity
  • Encephalitis & Encephalopathy
  • Endocrine Conditions
  • Epilepsy and Seizures
  • Gastrointestinal
  • Heart Disease
  • Hematological Disorders
  • HIV/AIDS Progression
  • Immunity & Immunotherapy
  • Infertility & Miscarriage
  • Kidney Disease
  • Liver Disease
  • Lung Disease
  • Lymphadenopathy & Fever
  • ME/CFS
  • Multiple Sclerosis
  • Rash & Roseola
  • Transplant Complications
  • Treatments – Adoptive T cell
  • Treatments – Alternative
  • Treatments – Antiviral
  • Treatments – Immune Stimulant

Scientific News

  • Latest Scientific News

About HHV-6

  • What Is HHV-6?
  • What is Inherited Chromosomally Integrated HHV-6
  • HHV-6 Repository of Reagents
  • HHV-6A/B Testing
  • HHV-6 Treatment

SUBSCRIBE TO OUR NEWSLETTER

ABOUT THE HHV-6 FOUNDATION

The HHV-6 Foundation in a non-profit entity founded to encourage scientific exchange between investigators and to provide pilot grants for promising scientific and clinical research on the under- appreciated viruses HHV-6A and HHV-6B.

The Foundation sponsors international conferences and supports scientists and clinicians seeking to clarify the role of the two HHV-6 viruses in disease. Since HHV-6A and HHV-6B can smolder in the brain and other organs without circulating in the peripheral blood or plasma, identifying chronic infection is a challenge.

Read More

HHV-6 Foundation | 1482 East Valley Road, Suite 619 | Santa Barbara, CA, 93108 | Toll Free: (888) 530-6726


Copyright ©2004-2022 HHV-6 FOUNDATION


WEB DESIGN AND DEVELOPMENT BY INSTYLE TECHNOLOGIES
  • Home
  • About
  • Conditions
  • Clinicians
  • Testing
  • Research
  • Repository
  • Patients
  • Treatment
  • News & Blog
  • Donate
  • Contact Us
  • Cart
  • Checkout
  • Privacy Policy
  • Terms of Use